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Glucolipotoxicity initiates pancreatic β-cell death
through TNFR5/CD40-mediated STAT1 and NF-κB
activation
Marta Bagnati1,6, Babatunji W Ogunkolade1,6, Catriona Marshall1, Carmen Tucci2, Katie Hanna2, Tania A Jones1, Marco Bugliani3,
Belinda Nedjai4, Paul W Caton5, Julius Kieswich1, Muhammed M Yaqoob1, Graham R Ball2, Piero Marchetti3, Graham A Hitman1 and
Mark D Turner*,2
Type 2 diabetes is a chronic metabolic disorder, where failure to maintain normal glucose homoeostasis is associated with, and
exacerbated by, obesity and the concomitant-elevated free fatty acid concentrations typically found in these patients.
Hyperglycaemia and hyperlipidaemia together contribute to a decline in insulin-producing β-cell mass through activation of the
transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of
transcription (STAT)-1. There are however a large number of molecules potentially able to modulate NF-κB and STAT1 activity, and
the mechanism(s) by which glucolipotoxicity initially induces NF-κB and STAT1 activation is currently poorly defined. Using high-
density microarray analysis of the β-cell transcritptome, we have identified those genes and proteins most sensitive to glucose and
fatty acid environment. Our data show that of those potentially able to activate STAT1 or NF-κB pathways, tumour necrosis factor
receptor (TNFR)-5 is the most highly upregulated by glucolipotoxicity. Importantly, our data also show that the physiological ligand
for TNFR5, CD40L, elicits NF-κB activity in β-cells, whereas selective knockdown of TNFR5 ameliorates glucolipotoxic induction of
STAT1 expression and NF-κB activity. This data indicate for the first time that TNFR5 signalling has a major role in triggering
glucolipotoxic islet cell death.
Cell Death and Disease (2016) 7, e2329; doi:10.1038/cddis.2016.203; published online 11 August 2016
In 2011, it was estimated that there were 347 million people
worldwide living with diabetes.1 Moreover, the incidence of
diabetes continues to grow at an alarming rate, with the figure in
2030 projected to be more than double that reported in 2000.2
There are a limited number of options to treat type 2 diabetes
(T2D), and furthermore oral and injectable medications often
become less effective over time. Thus, there is an urgent need to
better understand the causes of diabetes, and to identify new
targets for the development of novel treatment strategies.
Hyperglycaemia and hyperlipidaemia together contribute to
the gradual loss of β-cell function that has been observed in
patients with T2D. In addition to the failure of compensatory
hypersecretion to overcome insulin resistance, reduction in
β-cell mass through increased apoptosis is a key component
of T2D.3,4 Increased metabolic stress results in the activation
of the transcription factors nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB)5,6 and signal transducer
and activator of transcription (STAT)-1.7 These then trigger
the synthesis of a number of β-cell proteins, including the
cytokine interleukin (IL)-1β.8 This is then released from the
cell, whereupon it is able to bind the β-cell surface IL-1
receptor and amplify both NF-κB activation and the subse-
quent cytokine response that is driven through activation of
nucleotide-binding oligomerization domain receptor family,
pyrin domain containing 3 inflammasomes.5 In addition,
inflammasome activation can also lead to caspase-1-
mediated cell death through a process termed pyroptosis,
which both fragments DNA and leads to pore formation in the
plasma membrane.9
Aswell as these IL-1β-mediated cytokine response pathways,
a number of chemokines are also synthesised and released by
β-cells following glucolipotoxic activation of NF-κB.5 These serve
to attract circulating immune cells, which then infiltrate
the pancreas and are specifically drawn towards β-cells.10,11
Here these immune cells release their own cocktail of cytokines.
Along with glucolipotoxicity-induced β-cell IL-1β release, this
localised toxic milieu effectively destroys β-cells.
Although we know many of the events resulting from NF-κB
activation, the initial trigger of glucolipotoxic NF-κB activation
remains poorly defined. Endoplasmic reticulum (ER) stress is
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one mechanism that has been proposed to initiate this
response.12 However, as ER stress is typically induced by
an increase in the synthesis of client proteins, this is more
likely to occur in response to increased transcriptional activity
and the resulting increase in protein synthesis and ER
throughput. Hence, ER stress is more likely to be a conse-
quence rather than cause of the increased transcriptional
activity and/or islet inflammation. There are some exceptions,
such asWolfram syndromewhere there is a codingmutation in
the protein wolframin that is thought to regulate ER Ca2+ flux
and thereby ensure protein fidelity and the degradation of
misfolded proteins.13 However, as this and similar genetic
disorders are relatively rare they are unlikely to contribute to
ER stress in the majority of people with T2D.
Oxidative stress is another mechanism commonly cham-
pioned, as the initial driver of gluco-or lipotoxic NF-κB
activation in β-cells. This is also questionable, however, since
reactive oxygen species (ROS) trigger a rapid spike in intra-
cellular Ca2+ that results in transient exocytosis of insulin.14,15
Indeed, there is increasing evidence to suggest that ROS
are essential for normal β-cell function, including insulin
secretion.16 Furthermore, some anti-oxidants potently inhibit
glucose-stimulated insulin secretion, not enhance it.17 This
may help explain why levels of the H2O2-inactivating enzymes
glutathione peroxidase and catalase are particularly low in
β-cells, when compared, for example, with expression level in
the liver.18 This does not mean that β-cells are incapable of
sustaining damage from excessive oxidative stress. However,
given the routine high glycolytic throughput of β-cells and the
general tolerance of β-cells against levels of ROS that would
be damaging to other cells, it would seem incongruous were
glucolipotoxicity to exert a disproportionately damaging effect
upon pancreatic function.
To more accurately define the initial mechanisms triggering
glucolipotoxicity-induced β-cell dysfunction, we used a combi-
nation of microarray expression profiling, independent quanti-
tative PCR analysis, western blotting, confocal microscopy, and
NF-κB activity assays to identify those genes and proteins,
whose expression is most sensitive to glucose and fatty acid
environment. Our data indicate that of the genes most likely to
be associated with cell death pathways, tumour necrosis factor
receptor (TNFR)-5 (also known as CD40) is the most highly
upregulated and is able to induce STAT1 and NF-κB activation.
Importantly, this pattern of upregulation was not restricted to rat
insulinoma cells alone, but also isolatedmouse islets from high-
fat-fedmice and human islets, indicating that thismay represent
a conserved cell death activation mechanism.
Results
To better understand the mechanisms by which chronic
exposure to high glucose and fatty acids alters cellular
function, we incubated INS-1 rat pancreatic β-cell insulinoma
cells for 72 h in Roswell Park Memorial Institute (RPMI)-1640
media and media supplemented with 28 mM glucose, 200 μM
oleic acid, and 200 μM palmitic acid. Total RNA was isolated
and hybridised to Affymetrix rat microarray chips (Santa Clara,
CA, USA). Approximately 10% of INS-1 transcripts underwent
a twofold or greater change in expression that was statistically
significant (Supplementary Appendix Table 1). This included
genes linked to apoptosis and related signalling pathways,
biological oxidation, nucleic acid processing, and repair
(Figure 1). To better understand how altered function in these
genes correlates with human disease, we employed Metacore
analysis algorithms (https://portal.genego.com) to identify the
25 diseases most closely associated with our data set.
Table 1 indicates the degree of significance, along with
enrichment expressed as the ratio of the number of genes
that would be expected to be associated to each specific
disease by chance (shown in green) compared with the
number of the differentially expressed genes enriched in our
data set (shown in red).
For molecules linked to inflammation and apoptosis, we
found changed expression in a number of tumour necrosis
receptor (TNFR) superfamily members and associated
factors. Of these TNFRSF5, the gene encoding TNFR5 was
found to be the most highly upregulated with 2.23-fold
expression (Po0.01; Table 2). To validate these results, we
Figure 1 Effect of glucolipotoxicity on β-cell ontology. Comparative analysis of gene expression from INS-1 cells incubated for 72 h in RPMI-1640 media supplemented with or
without 28 mM glucose, plus 200 μM oleic acid, and 200 μM palmitic acid. Data are compiled from six independent microarray analyses (three per experimental group).
Reactome pathway analysis (http://www.reactome.org) identified 13 significant biological functions/pathways (Po0.05)
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performed independent quantitative real-time PCR (qRT-PCR)
analysis of TNFRSF5, as well as the genes encoding TNFR1
and TNFR6 (also known as Fas) that have previously
been shown to mediate cytokine-induced islet inflammation
and apoptosis. Again, we observed significant increase in
TNFRSF5 expression (3.62-fold; Po0.01) induced by high
glucose and fatty acid environment (Table 2). TNFRSF1A
was also upregulated by greater than twofold, but variable
response meant that this was not deemed statistically
significant in the samples examined. TNFRSF6 by contrast
was only modestly upregulated, with this not found to be
statistically significant in the PCR experiments. As a conse-
quence, we focused our investigation on TNFR5 for the
remainder of this study.
Although our data indicate significant upregulation in
TNFRSF5 gene expression in β-cells exposed to a glucolipo-
toxic environment, mRNA does not always equate to protein.
Therefore, we incubated INS-1 cells for 72 h in RPMI-1640
supplemented with either 28 mM glucose, 200 μM oleic acid,
or 200 μM palmitic acid, both individually and in combination,
and immunoblotted with anti-TNFR5 polyclonal antibody. The
combination of glucose and fatty acids induced the strongest
(two- to threefold; Po0.01) upregulation in TNFR5 protein
(Figure 2a), although fatty acids or glucose alone also induced
upregulation albeit by amoremodest increase. These data are
supported by immunofluorescence experiments (Figure 2b),
in which there was a strong increase in TNFR5 intensity
(green) in INS-1 cells incubated for 72 h in the presence of
high glucose and fatty acids. Thus, a parallel increase in
protein levels assessed both by western blot an immunofluor-
escence was detected under glucolipotoxic conditions.
INS-1 tissue culture cells offer a consistent response to
experimental manipulation, whichmakes them an ideal choice
for microarray analysis where large numbers of repeat
experiments are costly. However, as transformed β-cell lines
are not always fully representative of primary β-cell biology, it
becomes important to determine whether these findings are
indicative of whole animal physiology. Therefore, C57Bl/6
micewere fed a high-fat diet for 10 weeks, resulting in impaired
glucose tolerance, diminished insulin secretion, and reduced
islet size. Pancreas was removed and total RNA extracted
from isolated islets. In line with our INS-1 cell data, qRT-PCR
analysis of extracted RNA showed a twofold increase in
TNFRSF5 expression in the high-fat-fed mice relative to lean
controls (Figure 2c). To determine whether our data were also
reflective of human physiology, we next isolated islets post-
mortem from human donors. These islets were incubated for
24 h in RPMI-1640 supplemented +/− 0.5 mM palmitate, total
RNA extracted, and qRT-PCR performed. Despite the shorter
incubation period, we again observed statistically significant
upregulation of TNFRSF5 (1.4-fold; Po0.05; Figure 2d),
indicative of a similar pattern of upregulation of TNFRSF5 in
rodent and human islets.
To identify wider TNFR5 pathway interactions, non-biased
network analysis was performed using the MetaCore inte-
grated knowledge database of pathways (https://portal.
genego.com). The gene content from microarray analysis
files was used as the input list for generation of biological
networks, using the analyse network algorithm with default
settings. This is a variant of the shortest paths algorithm with
main parameters of (1) relative enrichment with the uploaded
data and (2) relative saturation of networks with canonical
pathways. CD40L signalling through TNFR5 came out as the
top ranked of all upregulated networks irrespective of cellular
function. A further major finding from this analysis was the
central involvement of Janus kinase (JAK)/STAT signalling
pathways (Figure 3). As JAK/STAT signalling is often also
linked to additional cytokine signalling through interferon
(IFN)-γ-related pathways, we were able to assess the likely
validity of these predictions by going back to our original data
set and determining whether IFN-related genes showed
changed expression. Of the six genes that came through
our bioinformatic filter with statistically significant data, all six
were upregulated. Furthermore, upregulation of all six genes
was further confirmed by independent PCR analysis and
shown to be statistically significant (Po0.001; Supplementary
Appendix Table 2).
Table 1 Identification of associated diseases
Associated diseases Ratio P-value
Mental disorders 206/1593 1.212E−13
Psychiatry and psychology 233/1875 1.810E−13
Mood disorders 121/789 3.601E−13
Glioma 492/4765 6.519E−13
Neoplasms, neuroepithelial 511/4996 9.286E–13
Breast neoplasms 813/8688 3.199E–12
Breast diseases 813/8689 3.291E–12
Neoplasms, glandular and epithelial 808/8659 8.177E–12
Endocrine system diseases 564/5714 2.006E–11
Digestive system neoplasms 1044/11 780 1.513E–10
Skin diseases 993/11 125 1.770E–10
Rectal diseases 823/8967 2.047E–10
Gonadal disorders 334/3128 2.920E–10
Genital diseases, female 1129/12 925 3.174E–10
Pathological process 290/2642 3.419E–10
Astrocytoma 296/2709 3.514E–10
Genital neoplasms, female 1119/12 809 4.717E–10
Gastrointestinal neoplasms 940/10 509 8.836E–10
Ovarian neoplasms 313/2927 1.068E–09
Nutritional and metabolic diseases 328/3099 1.214E–09
Ovarian diseases 323/3046 1.370E–09
Adnexal diseases 323/3049 1.528E–09
Glioblastoma 286/2636 1.565E–09
Digestive system diseases 1071/12 231 1.672E–09
Intestinal neoplasms 839/9256 1.826E–09
INS-1 β-cells were incubated for 72 h in RPMI-1640 media supplemented
with or without 28 mM glucose, plus 200 μM oleic acid, and 200 μM palmitic
acid. RNA was extracted and hybridized to Affymetrix high-density microarrays
(Affymetrix). Differentially expressed genes were determined using Partek
software (Partek Inc., Chesterfield, MO, USA) based on a Po0.05 from three
independent experiments. Predicted associated diseases were identified using
MetaCore (http://genego.com) integrated knowledge database
Table 2 TNFR family member expression
TNFR1 TNFR5 TNFR6
Affymetrix — 2.23 (Po0.0001) 1.59 (Po0.05)
PCR 2.23 (P=NS) 3.62 (Po0.05) 1.19 (P=NS)
Abbreviations: NS, not significant; TNFR, tumour necrosis factor receptor
TNFR1, TNFR5, and TNFR6 expression was determined using Affymetrix
array data and independent qRT-PCR analysis. Data are shown from three
independent experiments
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To gain more detailed understanding of the contribution
of TNFR5 in triggering glucolipotoxic STAT1 and NF-kB
responses, we selectively modulated TNFR5 expression and
activity, and determined the resulting effect on STAT1 and
NF-κB. INS-1 cells were transfected with either scramble
sequence or short interfering RNA (siRNA) specifically
directed against TNFR5, then incubated for a further 72 h in
media supplemented with or without 28 mM glucose, 200 μM
oleic acid, and 200 μM palmitic acid. Although the scramble
sequence had no effect upon TNFR5 expression, the selective
oligonucleotide brought down expression of TNFR5 by
96.0 +/− 1.0% in cells cultured in standard RPMI-1640, and
by 97.8 +/− 1.3% in cells cultured in RPMI-1640 supplemen-
ted high glucose and fatty acids (Figure 4a). We then went on
to determine STAT1 expression in these cells. Culturing cells
for 72 h in media supplemented with high glucose and fatty
acids resulted in STAT1 expression more than doubling
(Figure 4b). However in cells where TNFR5 had been knocked
down (siRNA lanes), STAT1 expression decreased by 61.0
+/− 4.0% in cells cultured in standard RPMI-1640 media (left
panel), and by 54.6 +/− 2.9% in cells cultured in RPMI-1640
supplemented with high glucose and fatty acids (right panel).
We next investigated how glucolipotoxicity and TNFR5
activity affect NF-κB expression, localisation, and activity.
Following 72 h incubation in media supplemented with 28 mM
glucose and 200 μM fatty acids, we observed a 73.5 +/− 5.7%
increase in NF-κB expression (Figure 5a). Similarly, 6 h
exposure of INS-1 cells to 1 μg/ml CD40L (the physiological
activator of TNFR5) resulted in increased translocation of the
NF-κB p65 subunit to the nucleus (Figure 5b). Although this is
consistent with NF-κB activation by TNFR5, we nonetheless
sought to confirm this using a quantitative ELISA assay that
we have previously used to determine NF-κB activity in
nuclear extracts isolated from cells of patients with auto-
inflammatory fevers.19–21 Using this assay, we were also able
to compare NF-κB activity in β-cells treated with high glucose,
TNFα, or CD40L. As can be seen (Figure 5c), 72 h incubation
of INS-1 cells in 28 mM glucose resulted in an increased
level of NF-κB activity similar to that observed, following
2 h exposure of cells to 100 ng/ml of TNFα. However, under
low-glucose conditions where TNFR5 expression is not
upregulated beyond basal, 6 h exposure to 1 μg/ml CD40L
nevertheless still succeeded in eliciting half-maximal induction
of NF-κB activity.
Figure 2 TNFR5 protein expression in INS-1 β-cells, high-fat-fed mouse islets, and human islets. (a) INS-1 cells incubated for 72 h in RPMI-1640 media supplemented with or
without 28 mM glucose, 200 μM oleic acid, and 200 μM palmitic acid. Immunoblots were conducted using anti-TNFR5 primary antibody (Santa Cruz Biotechnology, Dallas, TX,
USA) and Li-Cor IR secondary antibody (Lincoln, NE, USA), and are representative of three independent experiments. (b) Imuunofluorescence of INS-1 cells fixed in 4%
paraformaldehyde for 30 min, then permeabilized with 0.1% Triton X-100. Samples were treated with anti-DAPI (blue; Life Technologies Ltd., Paisley, UK) or anti-TNFR5 primary
antibody (green), and incubated with secondary antibody conjugated to fluorescence dye (AF488; Life Technologies Ltd.). Images were taken with a Leica epi-fluo microscope
(Wetzlar, Germany) using either a 20 × objective (upper panels) or 40 × objective (lower panels), and in each case are representative of three independent experiments. (c)
C57Bl/6 mice were fed a high-fat or standard rodent diet for 10 weeks. Islets of mice were extracted and digested with collagenase, RNA extracted, reverse transcribed, and qRT-
PCR analysis performed. Data were analysed using theΔΔCT method from four independent experiments. (d) Human islets were cultured 24 h with or without 0.5 mM palmitate.
RNA was extracted, reverse transcribed, and qRT-PCR analysis performed. Data were analysed using the ΔΔCT method from six independent experiments. *Po0.05
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The above experiments detail how glucolipotoxicity influ-
ences TNFR5 expression and activity. They do not however
tell us whether the increased NF-κB activation is dependent
upon TNFR5, or is instead simply coincidental to increased
TNFR5 expression and activity. To address this point, we
again knocked down TNFR5 expression, then measured
NF-κB activity in mock-transfected cells, cells transfected with
scramble sequence, and cells transfected with selective
oligonucleotide. Although we were only able to achieve a
much more modest knockdown of TNFR5 in this particular
series of experiments (58.3 +/− 16.9%), this still significantly
ablated NF-κB activity by 46.7 +/− 8.2%.
Discussion
Using an unbiased high-density microarray screen, we have
been able to determine the effect of high glucose and fatty acid
environment on thousands of genes simultaneously. Among
the top 25hits, our, data indicates the presence of disease asso-
ciation with both endocrine and metabolic disorders, which
suggests the presence of pathways with known T2D and
obesity aetiology in man. Interestingly, the molecules differen-
tially expressed in this study were also found to be important
in other diseases. Of those diseases were a number of
brain disorders. This may reflect the pancreas being a highly
innervated organ that shares a number of molecular similarities
with brain at the level of transcriptome and proteome, the roots
to which likely lie in the fact that the pancreas contains ancestral
precursors of both pancreatic and neural crest origin.22 The
data also indicate changed expression of genes associatedwith
pathways common to many forms of neoplasm. Epidemiologic
evidence suggests that people with diabetes are at significantly
higher risk for many forms of cancer.23 Furthermore several
studies indicate an association between diabetes and risk of
liver, pancreatic, endometrial, colon/rectum, breast, and bladder
cancer. Although common risk factors such as age, obesity,
physical inactivity, and smoking undoubtedly contribute to the
increased cancer risk in diabetic patients, hyperinsulinemiamay
also increase the likelihood of developing cancer due to insulin
being a growth factor with metabolic and mitogenic effects. Its
action in malignant cells is also favoured by mechanisms acting
at both the receptor and post-receptor level.24
In agreement with the data presented here, it has previously
been shown that both human and murine pancreatic β-cells
Figure 3 Network analysis of TNFR5 signalling. MetaCore (http://genego.com)
was used to build a network from significantly upregulated genes in INS-1 cells
subjected to glucolipotoxicity. The most significant biological network (Po0.001)
included positive regulation of cellular, biological, and metabolic processes linked to
TNFR5 and JAK/STAT signalling. Details of network objects and interactions are
provided in the Metacore legend (Supplementary Appendix Figure 1). Thick cyan
lines indicate the fragments of canonical pathways. Upregulated genes are marked
with red circles
Figure 4 Effect of TNFR5 on STAT1 expression. (a) INS-1 cells were either
mock-transfected, transfected with scramble sequence RNA (ssRNA), or with specific
interfering oligonucleotide (siRNA). Cells were then incubated for 72 h in RPMI-1640
media supplemented with or without 28 mM glucose, plus 200 μM oleic acid, and
200 μM palmitic acid. Immunoblots were conducted using anti-TNFR5 primary
antibody (Santa Cruz Biotechnology). Alpha-tubulin was used for normalisation of the
data. TNFR5 protein expression fold-changes are expressed as mean± S.E.M. of
data obtained from three different experiments. (b) INS-1 cells were either mock-
transfected, transfected with ssRNA, or with siRNA oligonucleotide. Cells were then
incubated for 72 h in RPMI-1640 media supplemented with or without 28 mM
glucose, plus 200 μM oleic acid, and 200 μM palmitic acid. Immunoblots were
conducted using anti-STAT1 primary antibody (Cell Signalling Technology, Beverly,
MA, USA). Alpha-tubulin was used for normalisation of the data. Protein expression
fold-changes are expressed as mean±S.E.M. from data obtained from three
different experiments. *Po0.05, **Po 0.01, ***Po 0.001
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express functional TNFR5.25,26 Our observation that exposure
of β-cells to high levels of glucose and/or fatty acids results in a
two- to fourfold increase in expression of TNFR5may therefore
have clinical implications. However, without ligand activation
increased receptor expression is unlikely to have a significant
deleterious impact on functional β-cell mass. The pro-
apoptotic response to glucose and lipids is not restricted to
islet cells alone though. Previous work has shown that Indian
subjects with diabetes have approximately three times higher
soluble cluster of differentiation 40 ligand (sCD40L) levels in
their plasma than individuals with normal glucose tolerance.27
The same study also found that plasma sCD40L levels were
also elevated in people with impaired glucose tolerance,
metabolic syndrome, and insulin resistance. Other research-
ers reported similar findings in a subsequent study in
Europeans with T2D.28 Interestingly, this latter publication
also reported a significant decrease in platelet TNFR5
signalling following sustained reduction in haemoglobin A1C,
indicating that the process may be reversible. A positive
correlation between glycaemic control and sCD40L level has
also recently been reported in patients with type 1 diabetes.29
Our predictive pathway analysis indicates the potential for
TNFR5 to regulate a wide range of cellular functions, including
those that direct the ultimate fate of the β-cell – namely life and
regeneration through cell proliferation (STAT5 and MAP3K)
and cell cycle (cyclins and associated kinases), or cell death
(Bcl-2 and B-cell lymphoma-extra large). At the heart of each
of these pathways, however, lies NF-κB and/or STAT1.
Therefore, the combination of high sCD40L levels found in
diabetes and the upregulated expression of functional β-cell
receptor shown here suggests that TNFR5 signalling may be
responsible for much of the glucolipotoxicty-induced NF-κB
activity in humans. Furthermore, given that NF-κB5,6 and
STAT17 activity are known to subsequently lead to islet cell
death, we hypothesise that TNFR5 signalling likely represents
a major cause of islet cell death in people with poorly
controlled glucose homoeostasis and chronically elevated
levels of glucose and fatty acids.
As glucolipotoxic induction of both STAT1 and NF-κB
expression and activity can be prevented by downregulation
of TNFR5 expression this has major potential therapeutic
implications, not least as it might be possible to enhance islet
cell survival through targeted disruption of TNFR5 pathways.
Figure 5 Effect of TNFR5 signalling on NF-κB expression, localization, and activity. (a) INS-1 cells were incubated for 72 h in RPMI-1640 media supplemented with or without
28 mM glucose, plus 200 μM oleic acid, and 200 μM palmitic acid (GLT). Immunoblots were conducted using using anti-NF-κB p65 subunit primary antibody (Santa Cruz
Biotechnology). Beta-actin was used for normalization of the data. Data presented are representative of three independent experiments. (b) INS-1 cells were cultured onto
coverslips and incubated with CD40 ligand (1 μg/ml) for 6 h. Cells were then fixed and stained with anti-NF-κB p65 polycolonal antibody (green) and DAPI (blue). Images were
taken with a Leica EpiFluo microscope with a 63 × objective (representative image of three independent experiments). p65 translocation to the nucleus was quantified using
Image J. (c) INS-1 rat pancreatic β-cells were cultured in RPMI-1640 media supplemented with glucose, TNF, or CD40 at the indicated concentrations and for the duration stated.
NF-κB subunit activity was detected using TransAm ELISA kit (Active Motif, Rixensart, Belgium) directed against NFκB p65 subunits. Absorbance was measured at 450 nm, with
a reference wavelength of 655 nm. All experimental data were gathered from a series of three independent experiments. (d) INS-1 cells were either mock-transfected, transfected
with ssRNA, or with siRNA oligonucleotide, and cells then incubated for 72 h in RPMI-1640 media. NF-kB activity was quantified as outlined above. Experimental data were
gathered from a series of five independent experiments. *Po0.05
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Anti-TNFR5 strategies have previously been employed as a
general immunosuppressant strategy following transplanta-
tion, and also to treat people suffering from lupus and several
types of cancer. Intervention has not always met with success
however, as there are a number of reports where anti-CD40L
monoclonal antibodies have been shown to induce thromboem-
bolic events.30–33 Importantly, these dangerous side effects
have not been observedwhen the receptor, rather than ligand, is
targeted. Indeed, there are now numerous highly promising
clinical trials taking place, involving different anti-TNFR5
monoclonal antibodies.34,35 Of these, those employing antag-
onistic anti-TNFR5 antibodies are of particular relevance to our
current study. Lucatumumab is one such example that has been
found to be well tolerated,36 at least in moderate and
intermediate strength doses.37 Importantly, it has also been
shown to prevent induction of NF-κBactivity inmultiplemyeloma
cells.38 This strategywould need to bemodified for the treatment
of diabetes though, as immune cell interactions with the Fc
region of cell-bound lucatumumab could potentially lead to
either opsonisation of β-cells or antibody-dependent cell
cytotoxicity. Phage display technology may provide an alter-
native solution however, facilitating the generation of antibody
fragments containing the key heavy and light chain antigen
recognition sites, although lacking the Fc region of the full
molecule. This is an area that clearly warrants future research.
Materials and Methods
Materials. Antibodies were obtained from Santa Cruz Biotechnology Inc., Cell
Signalling Technology, and Li-Cor Bioscience. Unless otherwise stated, all other
chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA) or VWR
International Ltd (Lutterworth, UK).
Cell culture and islet isolation. INS-1 β-cells was cultured in RPMI-1640
media supplemented where indicated with 28 mM glucose, 200 μM oleic acid, or
200 μM palmitic acid for 72 h as detailed previously.39 C57Bl/6 mice (Charles River,
UK) were fed a high-fat (60% fat-58Y1; Test Diets, St. Lois, MO, USA) or standard
rodent diet for 10 weeks. Pancreas was surgically removed and digested in Hank's
buffered salt solution containing collagenase P (1 mg/ml) and DNAse I (0.15 mg/ml;
both Roche Diagnostics, Burgess Hill, UK). All animal experiments were conducted in
accordance with the UK Home Office Animals (Scientific Procedures) Act, 1986, with
local ethical committee approval. Human islets were isolated from non-diabetic
multiorgan donors as previously detailed,40 with approval of the local ethics committee
and with written informed consent from family members. In both cases, islets were
hand-picked into RPMI-1640 and immediately lysed for RNA or protein experiments.
Quantitative RT-PCR. Cells were trypsinised, washed with cold phosphate-
buffered saline (PBS) and lysed in RNAeasy QTL lysis buffer. Total RNA was
prepared from lysed cells using RNeasy kit (Qiagen, Hilden, Germany) according
to manufacturers recommended procedures (Qiagen). cDNA was generated from
RNA using a standard RT kit (Promega, Madison, WI, USA). qRT-PCR reactions
were performed using Maxima SYBR Green/ROX qPCR Master Mix (ThermoFisher
Scientific, Loughborough, UK) and the following primers: rat CD40 forward primer
GTCGGATTCTTCTCCAATG; rat CD40 reverse primer ACAGAGGGTATCAGT
CTGAC; mouse CD40 forward primer TGGTCATTCCTGTCGTGATG; and mouse
CD40 reverse primer GGCTCTGTCTTGGCTCATCT. Human islet experiments
were performed as previously described,41 with CD40 oligonucleotide obtained from
assay-on-demand gene expression products (Applied Biosystems, Foster City, CA,
USA). Target gene mRNA was quantified and normalised for β-actin using an
ABI7700 bioanalyzer (Applied Biosystems). Data were analysed using the ΔΔCT
method.
Affymetrix arrays. Quality and integrity of extracted RNA was assessed using
an Agilent Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA, USA). A measure
of 10 μg total RNA was converted into double-stranded cDNA using Superscript
Reverse Transcriptase kit (Life Technologies Ltd.), following manufacturer’s T7-(dT)-
based recommendation. T7 RNA polymerase was then used to convert the cDNA to
biotin-labelled cRNA. cRNA generated with T7 polymerase was chemically
fragmented, then hybridized overnight at 45 °C to Affymetrix high-density GeneChip
Rat Genome 230 2.0 arrays (Affymetrix), each containing 31 000 probe set, analysing
over 30 000 transcripts and variants from over 28 000 well-substantiated rat genes
following Affymetrix Expression Analysis Technical Manual procedures. Chips were
then washed and stained with streptavidin-phycoerythrin (SAPE). Signals were
amplified by incubation with biotinylated anti-streptavidin antibody (Vector Laboratories,
Burlingame, CA, USA) followed by a final SAPE staining step. Fluorescent pixel
intensities for each probe were determined using a confocal laser scanner (GeneArray
Scanner, Affymetrix), processed, quantified, background adjusted, and scaled using
Affymetrix Microarray Suite 5.0 software (Affymetrix). Further MAS 5.0 analysis
(Affymetrix) of scaled intensity data generated the absolute analysis for each probe, as
well as comparative expression reading between two GeneChip arrays (Affymetrix).
Condition-to-condition differential expression profile analysis was carried out using
Genomics Suite (Partek Incorporated, St.Louis, MO, USA). Principal component
analysis was applied to identify any independent sources of variation in the data.
Pathway identification and visualisation. For comprehensive analysis
of biological pathways in which transcripts were differentially expressed we
combined expression data from the microarray analysis with information in
Reactome version 29, (http://www.reactome.org), a knowledgebase of biological
pathways.42 To visualise the networks, we used MetaCore (http://genego.com)
integrated knowledge database and software suite. Data analysis tools were used to
generate high-resolution images of networks, with details of network objects and
interactions provided in the Metacore legend (Supplementary Appendix Figure 1).
Western blotting. INS-1 cells were lysed and protein separated by SDS-
PAGE. Protein was then transferred to nitrocellulose as described previously.39
Protein was detected using either anti-STAT1 (Cell Signalling Technology), anti-
TNFR5, or anti-NF-κB p65 primary antibody (Santa Cruz Biotechnology), and
Li-Cor IR secondary antibody. Antibody binding was detected using the LI-COR Fc
Dual-Mode Imaging System (LI-COR).
Immunofluoresence. Cells were seeded in 12-well plates onto coverslips for
72 h in different media conditions, then fixed in 4% paraformaldehyde in PBS for
30 min and subsequently washed three times in PBS and store at +4 °C overnight.
The following day, cells were permeabilized by with 0.1% Triton X-100 in PBS for
5 min, washed in 0.1% Triton in PBS, then incubated in primary antibody for 2 h at
room temperature. Coverslips were then washed three times in PBS+Triton X-100
and then incubated with secondary antibody conjugated to fluorescence dye
(AF488, ThermoFisher Scientific) for 1 h at room temperature. Images have been
taken using a Leica DM5000 epi-fluo microscope.
Gene silencing. INS-1 cells were cultured to 40–50% confluency. siRNA
oligonucleotide was combined with diluted lipofectamine RNAi max and mixed
gently. After 25 min at room temp, the solution was mixed with RPMI and serum, but
without antibiotics. This was then added to cells for 24 h, after which it was replaced
with complete RPMI. Knockdown was detected 48–72 h after transfection by
western blot.
NF-κB activity. TransAM NF-κB Family Kits (Active Motif, Rixensart, Belgium)
were utilised for the study of specific NF-κB subunit pathways. In brief, oligonucleotide
containing an NF-κB consensus-binding site was immobilized onto 96-well plates. The
binding of NF-κB to its consensus sequence was detected by adding 30 μl of
complete binding buffer to each well and 1 μg of nuclear extract diluted in complete
lysis buffer was then added per well. The plates were sealed and incubated for 1 h at
room temp with mild agitation. Each well was then washed three times with 200 μl
1 × wash buffer. Antibody directed against one of NF-κB p65 subunit was bound to
the protein-oligonucleotide complex and detected following addition of secondary
antibody, conjugated to horse radish peroxidase. Developing solution was added and
the plate was incubated for 2–10 min at room temperature. Absorbance was then
measured, using a spectrophotometer (Perkin Elmer-Wallac, Milan, Italy) Victor-1420
multi-label counter at 450 nm with a reference wavelength of 655 nm.
Statistical analysis. Results are expressed as mean±S.E.M. (n= 3 or more
independent experiments). Parameters were compared using unpaired Student's
t-test and a P-value ofo0.05 was considered significant.
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